Abstract The literature contains a number of controversies regarding key questions: (
Introduction
The most definitive diagnostic procedure for most musculoskeletal tumors is a biopsy. However, not all musculoskeletal lesions require treatment or a biopsy. Certain benign and low-grade chondroid bone lesions can be observed over time to see if the lesion is increasing in size or developing new radiographic features. Likewise, many small soft tissue masses (such as cysts, small lipomas, inflammatory nodules, dermatofibroma, or other benign fibrous lesions) do not need surgical treatment. Large, deep lipomatous masses can be diagnosed with a carefully performed MRI. Most other lesions, particularly those greater than 4 cm in greatest dimension, will require histologic evaluation to confirm the diagnosis.
Biopsy of musculoskeletal lesions should be carefully planned and performed after radiographic staging studies are completed. This allows for correlation of radiographic and histologic findings. Radiographic studies performed after biopsy can have artifact from the surgery that confounds accurate interpretation. Several issues arise concerning the biopsy of musculoskeletal soft tissue masses. Because it is estimated as many as one-fourth of adults have small soft tissue masses at some time in their life, and only one of 200,000 people will develop soft tissue sarcoma, an appropriate clinical screening mechanism is necessary to avoid overuse of biopsy and underdiagnosing sarcoma. Defining how the biopsy should be performed to maximize diagnostic accuracy and minimize morbidity is critical. Understanding who is best suited to perform the biopsy (ie, radiologist, primary care physician, general surgeon, general orthopaedic surgeon, orthopaedic oncologic surgeon) should be clarified if, in fact, there is a difference in outcome.
Therefore, the authors believe the following questions important to explore the literature and provide clinical guidelines: (1) When is a biopsy indicated? (2) How should the biopsy be placed? (3) How should the biopsy be performed (open incisional biopsy, core needle biopsy, fine needle aspiration biopsy) and which has the greatest diagnostic accuracy? (4) Who should perform the biopsy (radiologist, sarcoma pathologist, general pathologist, general surgeon, general orthopaedic surgeons, orthopaedic oncologic surgeon)? (5) What clinical parameters present the greatest diagnostic difficulty?
Materials and Methods
In 2006, the Musculoskeletal Tumor Society assembled a subcommittee for evidence-based medicine that consisted of the four authors (all orthopaedic tumor surgeons with extensive clinical experience who are active in the diagnosis and treatment of patients with soft tissue masses). They provided input as to key questions concerning biopsy of soft tissue masses, reviewed the literature, and met with consensus as to the conclusions, literature cited, clinical guidelines, and remaining unanswered questions.
To identify all original human research of effectiveness of biopsy of soft tissue masses, we performed a literature search of all English manuscripts from 1966 to 2007 using PubMed and Google Scholar electronic search using the words ''biopsy musculoskeletal masses'' and ''soft tissue biopsies.'' Boolean operators ''not'' were used to exclude the following terms: kidney, renal, prostate, skin, lung, liver, node, esophagus, abscess, breast, and seroma. This resulted in 2211 and 1980 references from the two searches, respectively. Clinical studies were censored (99%) based on abstract content if they were case reports (22.4%), review or opinion articles (22%), radiographic study of a technique or retrospective review of patients with known diagnostic entities (21%), biopsy of bone lesions (14.5%), not a biopsy paper (13.1%), biopsy of metastatic carcinomas of bone and soft tissue (5%), or a duplicate paper to a previously accepted reference (1%). This left 41 references (1%) whose manuscripts were reviewed completely by two authors (BTR, AA). Thirty-two of 41 total papers were included in this review because they reported biopsy data that were limited to the biopsy of soft tissue masses (28 found with both Google Scholar and PubMed, three found with PubMed alone, and one with Google alone). Nine of 41 references were excluded because they included bone biopsies comingled with the soft tissue masses and/or did not give diagnostic accuracy results of biopsies. To ensure a comprehensive literature search, all four authors reviewed bibliographies of all included articles and all review articles concerning biopsy. No additional references were found with these methods. After the manuscript was finalized, it was sent electronically to all members of the Musculoskeletal Tumor Society to review on two separate occasions. Three articles were questioned by the membership as to their exclusion by this society review. All three articles had been identified by our literature search and were excluded because they included bone biopsy results (nine of 41 papers that included bone biopsy results). No additional references were otherwise identified by the society membership.
Two authors (BTR, AA) independently screened the 32 referenced soft tissue biopsy articles for level of evidence based on the criteria espoused by Clinical Orthopaedics and Related Research (Table 1) . Level I evidence was designated in any study that used a high-quality randomized, prospective trial with 80% or greater followup with a statistically significant difference or no statistically significant difference but narrow confidence intervals. Level II was given to studies that were lesser-quality clinical trial that may include retrospective data or lower-quality prospective data with less than 80% followup. Level III was given to retrospective, case-control studies of nonconsecutive patients. Level IV was given to retrospective case series with a poor reference standard and no sensitivity analysis. No editorial reviews or case reports were included in this analysis. There was no disagreement between reviewers on this level of evidence analysis of the 32 referenced papers.
The papers included in the review were then studied to determine (1) who performed the biopsy; (2) the accuracy of distinguishing benign from malignant lesions; (3) the accuracy in predicting a definitive diagnosis; and (4) the accuracy of predicting grade of the tumor. Papers that did not include percentage of nondiagnostic results in their percentage of accuracy were so noted or had accuracy percentage calculated from their raw data (see Appendix 1) .
The American Academy of Orthopaedic Surgeons Guideline recommendation classification was used. Practice guideline recommendation classification was ''We recommend = A'' for EBM Level I studies; ''We suggest = B'' based on EBM Level II or III; and ''Option = C'' based on EBM Level IV [4] . 
Results
(1) When is a biopsy indicated? No referenced evidencebased articles addressed when a biopsy of a soft tissue mass was indicated. In fact, large variability in the incidence of neoplastic and nonneoplastic lesions was noted in the referenced articles. This variability resulted in confounding results of diagnostic accuracy of needle biopsy, particularly when larger inflammatory, infectious, and myxoid lesions were sampled. In the absence of any evidence-based data, the authors offer their opinions on this question. A biopsy is indicated whenever a mass has biologic activity and further surgical or medical treatment will be based on that result. Because many musculoskeletal lesions are inactive processes, many lesions do not require a biopsy or treatment. (a) Soft tissue masses larger than 3 cm are more likely to require biopsy. Masses that are actively growing or symptomatic are lesions that may require biopsy. (b) A soft tissue ''hematoma'' that is not associated with trauma, has no history of ecchymosis, and is increasing in size or symptoms may require biopsy. Suspected hematomas that do not resolve over time may need a biopsy.
(2) How should the biopsy be placed? (a) None of the referenced evidence-based articles addressed technical aspects of biopsy placement. In the absence of evidencebased data, the authors offer their opinions on this question. The procedure of biopsy is a simple technical skill but a difficult cognitive skill. The biopsy must be carefully planned and placed so definitive resection of the tumor is not limited or compromised. The surgeon must respect the following principles whenever tissue is removed from the body, because any time tissue is removed, it should be considered a biopsy. Failure to send tissue to pathology or process it appropriately is a particularly distressing problem and may be the fault of the surgeon, the operating room staff, or the staff of the facility, particularly when biopsies are rarely performed. Complete hemostasis during the biopsy is critical to prevent hematoma dissection outside of the tumor bed, which could potentially transport tumor cells into wider or newer areas. The biopsy tract must be placed in a location that is resectable at the time of tumor excision (if the lesion is malignant). Excision of the biopsy tract, all contaminated tissues, and the tumor as one piece with adequate surgical margins is necessary at the time of sarcoma resection for optimum local control. This requires longitudinally placed extremity incisions and biopsies that do not expose critical neurovascular structures that could become contaminated with sarcoma. This requires the biopsy incision be placed in a position that can be safely excised en bloc with the resected specimen. (b) No referenced study addressed whether needle biopsy placement affected local control or survival of patients with soft tissue sarcoma. Case reports of local recurrences in unresected needle biopsy tracts have been separately reported.
(3) How should the biopsy be performed? Five referenced studies addressed this question. One study had EBM Level I evidence [32] , one Level III [2] , and three Level IV [9, 10, 33] . The first objective of a biopsy is to obtain diagnostic material. If the biopsy is performed in conjunction with frozen section histology additional tissue may be obtained if the frozen section is initially nondiagnostic. This can be accomplished with fine needle aspiration (FNA), trocar (or cutting needle), open incisional biopsy, or open excisional biopsy (based on recommendation Grade A). (a) FNA had a lower diagnostic accuracy compared with core needle biopsy in five studies that addressed this comparison [32] . (b) Incisional biopsy was associated with a 94% diagnostic accuracy and was more accurate than core biopsy (83%) but at a much higher expense [27] ; EBM Level II. (c) Excisional biopsy should be reserved for carefully selected clinical situations such as small subcutaneous tumors or lesions that have a diagnostic MRI appearance. No referenced EBM article addressed diagnostic accuracy of excisional biopsy.
(4) Who should perform the biopsy? Radiologists, pathologists, general surgeons, general orthopaedic surgeons, and sarcoma specialists were all represented in these studies [1] [2] [3] (based on recommendation Grade B). Needle biopsies performed by all physicians had equal rates of diagnostic accuracy whether or not they were at a sarcoma center [12] ; EBM Level III. Needle biopsy performed with computed tomography, ultrasound, or MRI assistance can improve quality of diagnostic material, but this is not supported by the EBM articles studied [1, 9, 12, 13, 21-23, 29, 31, 33] ; EBM Level IV. The highest diagnostic accuracy results were reported by core needle biopsy performed by surgeons [2, 24, 26, 27] ; EBM Level IV. However, this may be explained by a selection bias whereby the most difficult diagnostic cases in the worst anatomic locations were excluded as a result of clinical and radiographic clues by surgeons. Frozen section at the time of biopsy improves diagnostic accuracy 6% to 8% [9] , but this is based on EBM Level IV. Therefore, a recommendation cannot be supported by the current literature about the use of frozen section to rationalize the increased cost. The complications reported in four studies ranged from 0% to 2% [5, 6, 15, 23] ; EBM Level IV.
(5) What clinical parameters present the greatest diagnostic difficulty? Three articles addressed this question (based on recommendation Grade B). (a) Myxoid, infection, and round cell histology were associated with the lowest diagnostic accuracy rate with needle biopsies [10, 21] . (b) The paraspinal anatomic location had the lowest diagnostic accuracy rate [8] .
Discussion
Our report is one of a subcommittee of the Musculoskeletal Tumor Society. We began our charge by agreeing on five important questions concerning biopsy of soft tissue masses: (1) When is a biopsy indicated? (2) How should the biopsy be placed? (3) How should the biopsy be performed and which has the greatest diagnostic accuracy? (4) Who should perform the biopsy? (5) What clinical parameters present the greatest diagnostic difficulty? The report was presented to and accepted by the MSTS after their meeting November 6-8, 2008 .
Perhaps the most profound finding of this study was the literature on this subject is very sparse despite the fact that the biopsy is a critical step in the routine treatment of soft tissue tumors that dictates treatment options. We only identified 32 studies that provided evidence about biopsy of soft tissue tumors and only two of the 32 studies had Level I or Level II evidence. Of the five questions that the authors proposed, two were not addressed by the literature. This lack of evidence should encourage investigators to study these issues to allow us to answer these questions confidently.
In terms of comparing accuracy of open biopsy, core biopsy, and FNA, the five studies that addressed this suggested open biopsy was the most accurate modality, but the authors do not believe the level of evidence is strong enough to suggest one biopsy technique over another. Therefore, all three modalities are acceptable biopsy techniques for soft tissue masses.
Likewise, there is insufficient evidence to suggest which specialty is preferred to perform the biopsy. Although there is Level IV evidence that surgeons performing core biopsies have the highest accuracy, it is likely biased in that the simplest diagnostic cases are biopsied with core biopsy and the more challenging cases undergo open biopsy or computed tomography-directed needle biopsy.
Concerning diagnostic problems, myxoid and round cell neoplasms, infections, and paraspinal anatomic location have the lowest diagnostic accuracy with needle biopsy [9, 20] .
After evaluating the current literature, future research should be explored. First, examining the role of frozen section at the time of core needle biopsy should be done. Frozen section adds to the complexity of performing the biopsy because it would be difficult in many clinical settings and add to the cost of the biopsy considerably. Another area of some controversy but also poorly covered in the literature is the role of excisional biopsy. At what size soft tissue tumor is it no longer appropriate to perform excisional biopsy? What is the morbidity and impact on limb salvage? Another powerful question to explore is to address whether there are diagnostic accuracy differences between specialists performing the biopsy and whether it impacts local control. A study of the clinical and radiographic parameters that suggest biopsy over observation is needed. Does the addition of three-dimensional radiologic support during the biopsy increase the accuracy and justify the greater cost? A prospective, randomized study analyzing the diagnostic accuracy, the morbidity, and the cost of FNA versus open biopsy versus core needle biopsy for soft tissue masses is very important. EBM Level IV: Sarcoma surgeon performed core biopsy with 94% accuracy (includes 4% inadequate tissue) for malignancy, 85% accuracy for subtype, and 88% accuracy for grade. Tru-Cut biopsies were obtained from 52 consecutive patients referred with soft tissue tumors. Of the biopsies, 96% provided adequate material for diagnosis. The accuracy of Tru-Cut biopsy was 98% for the diagnosis of malignancy and 94% for the diagnosis of sarcoma. Tumor subtype was correctly specified in 85% of sarcomas and tumor grade in 88%.
3 18) for the extra-articular soft tissue lesions, and 71% (five of seven) for the intra-articular soft tissue lesions. With regard to the diagnostic accuracy, the sensitivity was 0.86, the specificity was 1.00, the PPV was 1.00, and the negative predictive value was 0.76 in the overall group. The respective values were 0.92, 1.00, 1.00, and 0.86 for the bone lesions; 0.77, 1.00, 1.00, and 0.57 for the extra-articular soft tissue lesions; and 1.00, 1.00, 1.00, and 1.00 for the intra-articular soft tissue lesions. There was one complication: exacerbation of neuropathic pain related to a biopsy of a peripheral nerve sheath tumor. EBM Level IV: Computed tomography-guided core needle biopsies and fine needle aspirates were performed on 359 musculoskeletal lesions. The overall accuracy was determined to be 71%. The accuracy for 101 FNAs was 63% and for 258 computed tomography-guided core biopsies was 74%. It is of note that the biopsies of 81 pelvic lesions had higher rates of diagnostic accuracy (81%) than those of 278 nonpelvic sites (68%), and especially 94 lesions of the spine (61%). The lowest success rates occurred in 26 patients with infectious diseases (50%).
10. Hodge JC. Percutaneous biopsy of the musculoskeletal system: a review of 77 cases. Can Assoc Radiol J. 1999;50:121-125.
EBM Level IV: A total of 77 percutaneous biopsies were performed under computed tomographic or fluoroscopic guidance of 63 bone and 14 soft tissue biopsies. No followup information was available for eight patients, and one patient died before an accurate diagnosis could be made. There were 44 true-positive, 17 true-negative, eight false-negative, and no false-positive results. The correct diagnosis was obtained in 57 of 68 cases (83.8%). For bone biopsies, the accurate diagnosis was obtained in 47 of 55 cases (85.5%). For soft tissue biopsies, the correct diagnosis was obtained in 10 of the 13 cases (76.9%). Diagnostic accuracy was slightly better for osteolytic than for osteosclerotic lesions. Accuracy also varied with lesion site and needle type. Cytology and pathology specimens were almost equally useful in contributing to the correct diagnosis. EBM Level IV: There were 80 soft tissue and 135 bony lesions. All biopsies were performed by the same radiologist and the histologic examination by the same pathologist. Of the 80 soft tissue biopsies, 35 were malignant (25 soft tissue sarcomas, six lymphomas, four metastatic carcinomas); 40 were benign (myositis ossificans, neurofibroma, desmoid tumor, schwannoma, hematoma, and others), and five were inconclusive and followed by an open incisional biopsy. The core needle biopsy histologic diagnosis was compared with that of the definitive surgery and the diagnostic accuracy was 90%.
Only three samples initially diagnosed as benign turned out to be malignant. No significant complications occurred during the procedures.
13. Kissin MW, Fisher C, Carter RL, Horton LW, Westbury G. Value of Tru-Cut biopsy in the diagnosis of soft tissue tumors. Br J Surg. 1986;73:742-744.
EBM Level IV: Tru-Cut needle biopsies from 50 consecutive soft tissue tumors were assessed by three pathologists and compared with the definitive histologic diagnosis. A correct predictive diagnosis of sarcoma was made on 87% to 98% of adequate Tru-Cut specimens, the accuracy varying between pathologists. Three sources of diagnostic error were recognized: false-positive cores (8%), false-negative cores (8%), and cores inadequate for diagnosis (16%).
14. EBM Level IV: The diagnoses were determined on 163 core needle biopsies (bone, 91; soft tissue, 72) performed on 157 consecutive patients. One hundred forty-three specimens (88%) were determined to be adequate for histologic examination. A pathologist with experience in musculoskeletal lesions was able to differentiate malignant tumors from benign lesions in 97% of the cases (bone, 100%; soft tissue, 94%) and arrive at a specific diagnosis in 88% (bone, 96%; soft tissue, 78%) when adequate cores were obtained. The overall accuracy was 77% (bone, 85%; soft tissue, 68%). There was no morbidity related to the procedure. EBM Level IV: This was a prospective study to determine the accuracy of core needle biopsy in the diagnosis and grading of soft tissue tumors and to study the morbidity of core needle biopsy. Forty-one cases with 85.3% of core biopsies yielded an adequate sample. Core needle biopsy had a sensitivity of 90%, specificity of 100%, PPV of 100%, and a negative predictive value of 88.23%. Overall accuracy for diagnosis of malignancy was 94.28%, 77.7% of tumors were correctly subtyped, and none of them were histologically graded. EBM Level IV: The imaging features of 225 soft tissue tumors (179 benign, 46 malignant) in 222 patients were analyzed. By quantitative analysis, no single imaging feature or combination of features could reliably be used to distinguish benign from malignant lesions. For the subjective analysis, a correct and specific benign diagnosis could be made on the basis of MRI findings in 100 (44%) of the 225 tumors. For the entire cohort, the sensitivity was 78%, the specificity was 89%, the PPV was 65%, and the negative predictive value was 94% for a malignant diagnosis. When the diagnostic benign tumors were excluded, the specificity and negative predictive value decreased to 76% and 86%, respectively, whereas the sensitivity and PPV remained the same. EBM Level IV: One hundred thirty-six consecutive computed tomography-guided biopsy sessions were undertaken for musculoskeletal lesions in 128 patients. In 121 patients, a single session was sufficient to obtain representative material, whereas for six patients, two sessions and for one patient three sessions were necessary. One hundred eight biopsy sessions yielded a diagnosis, whereas 28 were inconclusive (diagnostic yield of 79.41%). Of 108 diagnostic biopsies, five were considered inaccurate (accuracy rate of 95.37%). The overall diagnostic yield and accuracy rate for soft tissue lesions were 70% and 92.85%. There were two complications with no permanent sequelae. EBM Level IV: Its diagnostic usefulness was investigated retrospectively in 110 patients with soft tissue masses (s-t-M) undergoing core needle biopsy between September 1994 and September 2000. One hundred three of 110 core needle biopsies were suitable for analysis. Core needle biopsy specificity and PPV were 100%; sensitivity was 95%, 99%, and 92%; and negative predictive value 85%, 95%, and 88% for diagnosing malignancy, soft tissue tumor, and sarcoma, respectively. Core needle biopsy sensitivity and negative predictive value were 100% for malignancy, connective tumor and sarcoma in lymphomas, high-grade sarcomas, and desmoid tumors. In low-grade sarcomas, sensitivity was 94% and 85% and negative predictive value 84% and 77% for malignancy and sarcoma, respectively. EBM Level IV: The pathologist at a sarcoma center using FNA was 83% accurate in predicting malignancy.
25. Serpell JW, Pitcher ME. Pre-operative core biopsy of soft-tissue tumors facilitates their surgical management. Aust N Z J Surg. 1998;68:345-349. EBM Level IV: All patients with primary soft tissue tumors managed by two surgeons with a special interest in soft tissue sarcomas since 1991 were reviewed. The overall accuracy of core biopsy was 84%. The sensitivity was 94% with 100% specificity. EBM Level I: Pathologist using both FNA and core biopsy in all patients found core needle biopsy was associated with a higher diagnostic accuracy of malignancy than FNA (93% versus 88%) and prediction of specific diagnosis (83% versus 64%).
32. Yeow KM, Tan CF, Chen JS, Hsueh C. Diagnostic sensitivity of ultrasound-guided needle biopsy in soft tissue masses about superficial bone lesions. J Ultrasound Med. 2000;19:849-855.
EBM Level IV: Authors evaluated the value of ultrasound-guided needle biopsy in 20 soft tissues masses. A diagnostic sensitivity of 95% and specificity of 100% in separating a benign or a malignant lesion was obtained. Fine needle aspiration cytology allowed the specific cell type of malignancy to be diagnosed in 80% of cases, whereas core needle biopsy allowed it in 91%. EBM = evidence-based medicine; FNA = fine needle aspiration.
